



June 26, 2024  
JCR Pharmaceuticals Co., Ltd.

Translation

## **Partial Correction: “Consolidated Financial Results for the Fiscal Year ended March 31, 2024 (FY2023)” (Japanese standard)**

June 26, 2024 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552: Chairman and President Shin Ashida, “JCR”) hereby announces that there have been corrections made to the “Consolidated Financial Results for the Year ended March 31, 2024 (FY2023)” (Japanese standard), which was filed on May 10, 2024. Corrections are highlighted as below.

### **1. Reason for Corrections**

After the announcement of “Consolidated Financial Results for the Year ended March 31, 2024 (FY2023),” partial errors were found in “Summary” and “Consolidated Financial Statements”. Hence the company has corrected the submitted financial results.

### **2. Details of Corrections**

Corrected parts are underlined.

1. Consolidated Financial Results for FY2023 (April 1, 2023 to March 31, 2024)

(1) Consolidated Operating Results (Cumulative)

[Before Correction]

(Percentage shows year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	million yen	%	million yen	%	million yen	%	million yen	%
Year ended March 31, 2024	42,871	24.8	7,531	51.4	7,264	34.1	5,507	46.0
March 31, 2023	34,343	(32.8)	4,975	(75.0)	5,418	(73.6)	3,772	(74.0)

(Reference) Comprehensive income: Year ended March 31, 2024: 6,836 million yen (76.1%)  
Year ended March 31, 2023: 3,881 million yen ([73.3]%)

[After Correction]

(Percentage shows year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	million yen	%	million yen	%	million yen	%	million yen	%
Year ended March 31, 2024	42,871	24.8	7,531	51.4	7,264	34.1	5,507	46.0
March 31, 2023	34,343	(32.8)	4,975	(75.0)	5,418	(73.6)	3,772	(74.0)

(Reference) Comprehensive income: Year ended March 31, 2024: 6,475 million yen (66.8%)  
Year ended March 31, 2023: 3,881 million yen ([73.3]%)

## 3. Consolidated Financial Statements

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income  
(Consolidated Statements of Comprehensive Income)

[Before Correction]

(Millions of yen)

	Fiscal year ended March 31, 2023	Fiscal year ended March 31, 2024
Profit	3,787	5,536
Other comprehensive income		
Valuation difference on available-for-sale securities	(63)	185
Deferred gains or losses on hedges	(0)	(0)
Foreign currency translation adjustment	147	<u>527</u>
Remeasurements of defined benefit plans, net of tax	11	153
Share of other comprehensive income of entities accounted for using equity method	—	434
Total other comprehensive income	94	<u>1,300</u>
Comprehensive income	3,881	<u>6,836</u>
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	3,834	<u>6,791</u>
Comprehensive income attributable to non-controlling interests	46	<u>45</u>

[After Correction]

(Millions of yen)

	Fiscal year ended March 31, 2023	Fiscal year ended March 31, 2024
Profit	3,787	5,536
Other comprehensive income		
Valuation difference on available-for-sale securities	(63)	185
Deferred gains or losses on hedges	(0)	(0)
Foreign currency translation adjustment	147	<u>166</u>
Remeasurements of defined benefit plans, net of tax	11	153
Share of other comprehensive income of entities accounted for using equity method	—	434
Total other comprehensive income	94	<u>939</u>
Comprehensive income	3,881	<u>6,475</u>
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	3,834	<u>6,430</u>
Comprehensive income attributable to non-controlling interests	46	<u>44</u>

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jp.jcrpharm.com](mailto:ir-info@jp.jcrpharm.com)

###